TRCCC 2018: Single-Cell TILs Polyfunctionality Associates with Clinical Outcome of Anti-PD-1 Therapy

IsoPlexis presented “Single-Cell Cytokine Profiling of Tumor-Infiltrating T Cells to Measure Patient Responses to Anti-PD-1 Therapy” at the Translational Research Cancer Centers Consortium (TRCCC) 2018 in Seven Springs, PA. The study found an association between CD8+ TILs polyfunctionality and the clinical outcome of melanoma patients on Anti-PD-1 therapy. TRCCC works to expedite the progress in immunotherapy and other biologic therapies. TRCCC brings together leaders in this field to advance science, collaboration and clinical trials to help individuals diagnosed with cancer.

Share This Article
Be in the Know.
The IsoPlexis Data Network
Join 10,000+ top scientists and receive industry pioneers' backed data straight to your inbox.
Your data is in safe hands: we’ll never sell it to third parties and you may always unsubscribe. Privacy Policy.